BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Fossils from China show complex life evolved millions of years earlier than once thought - 2Black Friday Paramount+ deal: Save 50% and stream these buzzy Taylor Sheridan shows
- 3Manual for Famous Beverages 2024
- 4Improving as a Pioneer: Examples from My Vocation
- 5Internet goes (cocoa) nuts: The funniest reactions to 12 tonne theft of KitKat bars
- Most loved Road Food: Which One Prevails upon You?
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- A milestone for Artemis II: Astronauts enter the 'lunar sphere of influence'
- Netanyahu expects Iran's leadership to fall
- Spots to Go Hang Floating
- All that You Really want to Be familiar with Dental Inserts Facilities
- Watch India launch advanced military satellite on rocket's 1st flight since May 2025 failure
- WATCH: IDF strikes, dismantles missile launchers in southern Lebanon
- Haifa refinery said hit in latest Iranian missile barrage
